BioXcel Therapeutics, Inc. (BTAI)Healthcare | Drug Manufacturers - Specialty & Generic | New Haven, United States | NasdaqCM
0.18 USD
-0.54
(-74.764%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 0.17 -0.01 (-0.009%) ⇩ (Aug. 28, 2026, 7:59 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 1:09 a.m. EDT
The immediate outlook is bearish due to a severe structural deterioration in the business, evidenced by five consecutive years of negative annual returns and a cumulative loss of over 96% since 2018. While the stock recently rallied from its lows, the underlying fundamentals are catastrophic: the company reports negative book value, massive debt relative to cash, and operating margins of -56%. The market has correctly priced this as a failing enterprise, rendering any short-term technical bounce a potential trap rather than a genuine opportunity. There is no dividend to provide income, and the lack of price history does not mitigate the reality that the core business is eroding shareholder value. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.190665 |
| MSTL | 0.193258 |
| AutoETS | 0.193781 |
| AutoTheta | 0.193887 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 28% |
| H-stat | 24.77 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.095 |
| Excess Kurtosis | -1.54 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.033 |
| Market Cap | 5,678,817 |
| Forward P/E | -0.12 |
| Beta | 0.29 |
| Website | https://www.bioxceltherapeutics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.81078947 |
| Address1 | 555 Long Wharf Drive |
| Address2 | 12th Floor |
| All Time High | 1,144.0 |
| All Time Low | 0.7 |
| Ask | 0.187 |
| Ask Size | 1 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 1,370,330 |
| Average Daily Volume3 Month | 1,016,100 |
| Average Volume | 1,016,100 |
| Average Volume10Days | 1,370,330 |
| Beta | 0.287 |
| Bid | 0.157 |
| Bid Size | 1 |
| Board Risk | 8 |
| Book Value | -3.688 |
| City | New Haven |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 7 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.1814 |
| Current Ratio | 0.209 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 0.2299 |
| Day Low | 0.1569 |
| Display Name | BioXcel Therapeutics |
| Earnings Call Timestamp End | 1,731,589,200 |
| Earnings Call Timestamp Start | 1,731,589,200 |
| Earnings Timestamp End | 1,774,531,800 |
| Earnings Timestamp Start | 1,774,531,800 |
| Ebitda | -44,507,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.186 |
| Enterprise To Revenue | 131.117 |
| Enterprise Value | 97,288,816 |
| Eps Current Year | -2.7 |
| Eps Forward | -1.57 |
| Eps Trailing Twelve Months | -0.65 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.97398 |
| Fifty Day Average Change | -0.79258 |
| Fifty Day Average Change Percent | -0.8137539 |
| Fifty Two Week Change Percent | -81.07895 |
| Fifty Two Week High | 4.29 |
| Fifty Two Week High Change | -4.1086 |
| Fifty Two Week High Change Percent | -0.95771563 |
| Fifty Two Week Low | 0.1569 |
| Fifty Two Week Low Change | 0.024499997 |
| Fifty Two Week Low Change Percent | 0.1561504 |
| Fifty Two Week Range | 0.1569 - 4.29 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,520,519,400,000 |
| Float Shares | 26,889,232 |
| Forward Eps | -1.57 |
| Forward P E | -0.1155414 |
| Free Cashflow | -31,745,500 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 29 |
| Fullday Change | -0.5374 |
| Fullday Change Percent | -74.7635 |
| Fullday Price | 0.172 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.53099996 |
| Gross Profits | 394,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.03601 |
| Held Percent Institutions | 0.25991 |
| Implied Shares Outstanding | 31,305,499 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,739,145,600 |
| Last Split Factor | 1:16 |
| Long Business Summary | BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. It also develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving sublingual film formulation of dexmedetomidine in Phase 3 trial for the treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer's disease, as well as opioid use disorder, alcohol use disorder with comorbid post-traumatic stress disorder, and acute stress disorder; and its immune-oncology candidate, BXCL701, which is an investigational oral innate immune activator that has completed Phase 1b/2a trial for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. In addition, the company engages in the development of BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. The company has collaborations with Columbia University, Yale University Medical School, and University of North Carolina for the development of BXCL501. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut. |
| Long Name | BioXcel Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 5,678,817 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_543567629 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -70,860,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 22,522,741 |
| Number Of Analyst Opinions | 3 |
| Open | 0.2122 |
| Operating Cashflow | -50,904,000 |
| Operating Margins | -56.00549 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 475 238 6837 |
| Post Market Change | -0.009399995 |
| Post Market Change Percent | -5.1819158 |
| Post Market Price | 0.172 |
| Post Market Time | 1,787,961,597 |
| Previous Close | 0.7188 |
| Price Eps Current Year | -0.067185186 |
| Price Hint | 4 |
| Price To Book | -0.04918655 |
| Price To Sales Trailing12 Months | 7.6533923 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.094 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.5374 |
| Regular Market Change Percent | -74.7635 |
| Regular Market Day High | 0.2299 |
| Regular Market Day Low | 0.1569 |
| Regular Market Day Range | 0.1569 - 0.2299 |
| Regular Market Open | 0.2122 |
| Regular Market Previous Close | 0.7188 |
| Regular Market Price | 0.1814 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 57,529,452 |
| Return On Assets | -1.02431 |
| Revenue Growth | 0.517 |
| Revenue Per Share | 0.033 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 6 |
| Shares Outstanding | 31,305,499 |
| Shares Percent Shares Out | 0.105900005 |
| Shares Short | 3,314,382 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 4,043,653 |
| Short Name | BioXcel Therapeutics, Inc. |
| Short Percent Of Float | 0.1078 |
| Short Ratio | 4.02 |
| Source Interval | 15 |
| State | CT |
| Symbol | BTAI |
| Target High Price | 38.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 18.33333 |
| Target Median Price | 12.0 |
| Total Cash | 12,841,000 |
| Total Cash Per Share | 0.41 |
| Total Debt | 104,451,000 |
| Total Revenue | 742,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.65 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.387945 |
| Two Hundred Day Average Change | -1.2065451 |
| Two Hundred Day Average Change Percent | -0.8693032 |
| Type Disp | Equity |
| Volume | 57,529,452 |
| Website | https://www.bioxceltherapeutics.com |
| Zip | 6,511 |